Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Jun;3(3):133-44.
doi: 10.1177/2042098612439884.

Safety of statins: an update

Miao Hu  1 , Bernard M Y Cheung  2 , Brian Tomlinson  1
Affiliations
Review

Safety of statins: an update

Miao Hu et al. Ther Adv Drug Saf. 2012 Jun.

Abstract

Statins are widely used and have been proven to be effective in the prevention of atherosclerotic vascular disease events, primarily by reducing plasma low-density lipoprotein cholesterol concentrations. Although statins are generally well tolerated and present an excellent safety profile, adverse effects from muscle toxicity and liver enzyme abnormalities may occur in some patients. Myopathy and rhabdomyolysis are rare with statin monotherapy at the approved dose ranges, but the risk increases with use of higher doses, interacting drugs and genetic predisposition. Asymptomatic increases in liver transaminases with statin treatment do not seem to be associated with an increased risk of liver disease. Therefore, statin treatment can be safely used in patients with mild to moderately abnormal liver tests that are potentially attributable to nonalcoholic fatty liver disease and can improve liver tests and reduce cardiovascular morbidity in this group of patients. The risks of other unfavorable effects such as the slightly increased risk of new-onset diabetes and potentially increased risk of haemorrhagic stroke are much smaller than the cardiovascular benefits with the use of statins.

Keywords: cardiovascular disease; drug safety; myopathy; rhabdomyolysis; statins.

PubMed Disclaimer

Conflict of interest statement

Professor Brian Tomlinson has received research funding to perform clinical studies from AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Kowa, Merck Serono, Merck Sharp and Dohme, Novartis, Otsuka, Pfizer, Roche, Sanofi-Aventis and Servier. He has acted as a consultant or speaker on occasions for AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Kowa, Merck Serono, Merck Sharp and Dohme, Novartis, Pfizer, Roche, Sanofi-Aventis, Schering-Plough, and Servier. The other authors have no known conflict of interest.

References

    1. Abd T.T., Jacobson T.A. (2011) Statin-induced myopathy: a review and update. Expert Opin Drug Saf 10: 373–387 - PubMed
    1. Ahmed W., Khan N., Glueck C.J., Pandey S., Wang P., Goldenberg N., et al. (2009) Low serum 25 (OH) vitamin D levels (<32 ng/mL) are associated with reversible myositis-myalgia in statin-treated patients. Transl Res 153: 11–16 - PubMed
    1. Alsheikh-Ali A.A., Karas R.H. (2007) Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration adverse event reporting system). Am J Cardiol 99: 379–381 - PubMed
    1. Amarenco P., Bogousslavsky J., Callahan A., 3rd, Goldstein L.B., Hennerici M., Rudolph A.E., et al. (2006) High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 355: 549–559 - PubMed
    1. Amarenco P., Labreuche J. (2009) Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol 8: 453–463 - PubMed

LinkOut - more resources